Literature DB >> 22942184

Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells.

Corey Smith1, Diah Elhassen, Stephanie Gras, Katherine K Wynn, Vijayendra Dasari, Judy Tellam, Siok-Keen Tey, Sweera Rehan, Yu Chih Liu, Jamie Rossjohn, Scott R Burrows, Rajiv Khanna.   

Abstract

T-box transcription factors T-bet (Tbx21) and Eomesodermin (Eomes) are critical players in CD8(+) cytotoxic T lymphocyte effector function and differentiation, but how the expression of these transcription factors is regulated remains poorly defined. Here we show that dominant T cells directed toward human CMV, expressing significantly higher levels of T-bet with graded loss of Eomes expression (T-bet(hi)Eomes(hi/lo)), are more efficient in recognizing endogenously processed peptide-major histocompatibility complexes (pMHC) compared with subdominant virus-specific T cells expressing lower levels of T-bet and high levels of Eomes (T-bet(int)Eomes(hi)). Paradoxically, the T-bet(hi)Eomes(hi/lo) dominant populations that efficiently recognized endogenous antigen demonstrated lower intrinsic avidity for pMHC, whereas T-bet(int)Eomes(hi) subdominant populations were characterized by higher pMHC avidity and less efficient recognition of virus-infected cells. Importantly, differential endogenous viral antigen recognition by CMV-specific CD8(+) T cells also correlated with the differentiation status and expression of perforin, granzyme B and K. Furthermore, we demonstrate that the expression of T-bet correlates with clonal expansion, differentiation status, and expression of perforin, granzyme B and K in antigen-specific T cells. These findings illustrate how endogenous viral antigen presentation during persistent viral infection may influence the transcriptional program of virus-specific T cells and their functional profile in the peripheral blood of humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22942184     DOI: 10.1182/blood-2012-03-420182

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response.

Authors:  Corey Smith; Dillon Corvino; Leone Beagley; Sweera Rehan; Michelle A Neller; Pauline Crooks; Katherine K Matthews; Matthew Solomon; Laetitia Le Texier; Scott Campbell; Ross S Francis; Daniel Chambers; Rajiv Khanna
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

2.  T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.

Authors:  Iulia Popescu; Matthew R Pipeling; Pali D Shah; Jonathan B Orens; John F McDyer
Journal:  J Immunol       Date:  2014-10-22       Impact factor: 5.422

3.  TOX2 regulates human natural killer cell development by controlling T-BET expression.

Authors:  Queenie P Vong; Wai-Hang Leung; Jim Houston; Ying Li; Barbara Rooney; Martha Holladay; Robert A J Oostendorp; Wing Leung
Journal:  Blood       Date:  2014-10-28       Impact factor: 22.113

4.  T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection.

Authors:  Wenjing Yi; Peixin Zhang; Yan Liang; Yun Zhou; Huanjun Shen; Chao Fan; Jonathan P Moorman; Zhi Q Yao; Zhansheng Jia; Ying Zhang
Journal:  Immunology       Date:  2016-12-07       Impact factor: 7.397

5.  Infection history determines the differentiation state of human CD8+ T cells.

Authors:  Michiel C van Aalderen; Ester B M Remmerswaal; Niels J M Verstegen; Pleun Hombrink; Anja ten Brinke; Hanspeter Pircher; Neeltje A Kootstra; Ineke J M ten Berge; René A W van Lier
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

6.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

7.  mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.

Authors:  Judy T Tellam; Jie Zhong; Lea Lekieffre; Purnima Bhat; Michelle Martinez; Nathan P Croft; Warren Kaplan; Ross L Tellam; Rajiv Khanna
Journal:  PLoS Pathog       Date:  2014-10-09       Impact factor: 6.823

8.  Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment.

Authors:  Hong Hanh Nguyen; Therasa Kim; Sang Yun Song; Somang Park; Hyang Hee Cho; Sung-Hoon Jung; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee; Hee-Ok Kim; Jae-Ho Cho; Deok-Hwan Yang
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

9.  T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection.

Authors:  Marcus Buggert; Johanna Tauriainen; Takuya Yamamoto; Juliet Frederiksen; Martin A Ivarsson; Jakob Michaëlsson; Ole Lund; Bo Hejdeman; Marianne Jansson; Anders Sönnerborg; Richard A Koup; Michael R Betts; Annika C Karlsson
Journal:  PLoS Pathog       Date:  2014-07-17       Impact factor: 6.823

10.  T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection.

Authors:  Rongshan Fan; Yinghua Lan; Jiwang Chen; Yanxin Huang; Qin Yan; Lisheng Jiang; Shupeng Song; Yongguo Li
Journal:  Virol J       Date:  2016-01-25       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.